Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry...

Area of Science:

• Cardiology
• Clinical Trials
• Health Services Research

Background:

• Coronary artery bypass graft (CABG) patients are often under-represented in acute coronary syndrome (ACS) clinical trials.
• This study compares the characteristics and outcomes of CABG patients who participated in a randomized trial versus those who entered a registry.

Purpose of the Study:

• To evaluate the differences in patient characteristics between trial participants and registry patients with ACS and prior CABG.
• To compare the primary efficacy and safety outcomes of invasive versus non-invasive management in these two groups over two years.

Main Methods:

• A randomized trial (CABG-ACS) allocated ACS patients with prior CABG to invasive or non-invasive management.
• Non-randomized patients were enrolled in a parallel registry.
• Primary efficacy and safety outcomes were independently adjudicated after a median follow-up of 694 days.

Main Results:

• Of 133 eligible patients, 60 entered the trial and 73 entered the registry.
• Registry patients exhibited greater comorbidity, including more valve disease, lower hemoglobin, worse heart failure class, and higher frailty.
• After two years, primary efficacy (43% trial vs. 49% registry) and safety outcomes (28% trial vs. 22% registry) were statistically similar between groups. EuroQol scores were lower in registry patients at one year.

Conclusions:

• ACS patients with prior CABG who did not participate in a randomized trial (registry patients) had higher baseline morbidity.
• Despite increased morbidity, registry participants experienced similar long-term efficacy and safety outcomes compared to trial participants.
• These findings suggest that registry data can provide valuable insights into the management and outcomes of CABG patients with ACS, even if they differ from trial cohorts.